智通财经APP讯,恩典生命科技(02112)发布2025年中期业绩,收入841.7万美元,同比增长41%;母公司拥有人应占溢利21.1万美元,上年同期亏损896.6万美元;每股基本盈利0.01美仙。
期内销售收入增加是由于植物干细胞销售渠道的扩张和客户数量的增加。
智通财经APP讯,恩典生命科技(02112)发布2025年中期业绩,收入841.7万美元,同比增长41%;母公司拥有人应占溢利21.1万美元,上年同期亏损896.6万美元;每股基本盈利0.01美仙。
期内销售收入增加是由于植物干细胞销售渠道的扩张和客户数量的增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.